Browse the corpus

Introduction About 71 million people are chronically infected with hepatitis C virus (HCV) and carry an elevated risk of developing liver disease including liver cirrhosis and hepatocellular carcinoma (HCC) [1]. HCV related deaths are approximated to be 399,000 annually [2]. Consequently, eradication of HCV is an essential endpoint as effective treatment has been associated with the reduction of hepatic fibrosis and decreased rates of HCC [3, 4]. Vitamin D is known to have regulatory roles in several infections as an immune modulator in both innate and adaptive immunity, principally via regulatory pathways of T-cell function [5-8]. Vitamin D deficiency is a very common observation among patients with the chronic liver disease, with nearly one third of these patients having severe vitamin D deficiency (< 12 ng/mL) [9]. This may be attributable to the impaired physiological conversion of inactive vitamin D to biologically active metabolites in chronic liver disease, which in turn is associated with severe fibrosis and reduced responsiveness to previously used interferon-based therapy [9].

severe vitamin D deficiency (< 12 ng/mL) [9]. This may be attributable to the impaired physiological conversion of inactive vitamin D to biologically active metabolites in chronic liver disease, which in turn is associated with severe fibrosis and reduced responsiveness to previously used interferon-based therapy [9]. Several studies have evaluated the role of vitamin D deficiency concerning interferon-based therapies, but there remains a paucity of literature which examines the influence of vitamin D levels with direct-acting antivirals (DAAs) response rates [10, 11]. We aim to assess the predictive value of pre-treatment serum vitamin D level for achieving sustained virologic response at 12 weeks post-treatment (SVR 12), defined as an undetectable viral load 12 weeks post-therapy. Secondary objectives included evaluating the prevalence of serum 25-vitamin D levels in HCV related cirrhotic cohorts. Patients and Methods The Institutional Review Board (IRB) approved the study protocol, and the patients were recruited from two specialty clinics attached to the two large community hospitals: Interfaith Medical Center and New York-Presbyterian Brooklyn Methodist Hospital. Patients A total of 291 consecutive chronic HCV infected patients treated with DAAs between January 2016 and December 2017 in the community clinic setting were retrospectively analyzed.

Patients and Methods The Institutional Review Board (IRB) approved the study protocol, and the patients were recruited from two specialty clinics attached to the two large community hospitals: Interfaith Medical Center and New York-Presbyterian Brooklyn Methodist Hospital. Patients A total of 291 consecutive chronic HCV infected patients treated with DAAs between January 2016 and December 2017 in the community clinic setting were retrospectively analyzed. Decompensated cirrhosis, hepatocellular carcinoma, history of liver transplant, and human immunodeficiency virus (HIV) co-infection were excluded from the study. None of the patients included in this study discontinued the treatment due to adverse events associated with treatment medications. The 25-hydroxyvitamin D levels were assessed before the start of therapy with chemiluminescence immunoassay; concentrations were recorded in ng/mL. Vitamin D deficiency was defined as a 25 (OH)-vitamin D serum level < 20 ng/mL, vitamin D insufficiency as 25 (OH)-vitamin D levels of 20 - 29.9 ng/mL, and normal vitamin D levels ≥ 30 ng/mL [12].

levels were assessed before the start of therapy with chemiluminescence immunoassay; concentrations were recorded in ng/mL. Vitamin D deficiency was defined as a 25 (OH)-vitamin D serum level < 20 ng/mL, vitamin D insufficiency as 25 (OH)-vitamin D levels of 20 - 29.9 ng/mL, and normal vitamin D levels ≥ 30 ng/mL [12]. All patients in this retrospective cohort study received at least 12 weeks of treatment with one of the recommended combination regimens in standard doses for chronic HCV infection. Three different treatment regimens were included in our study: ledipasvir (LDV) 90 mg/day + sofosbuvir (SOF) 400 mg/day , ledipasvir 90 mg/day + sofosbuvir 400 mg/day + ribavirin (RBV) 1,000 mg/day if < 75 kg and 1,200 mg/day if ≥ 75 kg, (ombitasvir 12.5 mg + paritaprevir 75 mg + ritonavir 50 mg) two tablets twice daily + dasabuvir 250 mg twice daily, ombitasvir (OBV) 12.5mg + paritaprevir (PTV) 75mg + ritonavir (r) 50 mg two tablets twice daily plus dasabuvir (DSV) 250 mg twice daily + ribavirin 1,000 mg/day if < 75 kg and 1,200 mg/day if ≥ 75 kg, and sofosbuvir 400 mg/day + velpatasvir (VEL) 400 mg/day. Duration of treatment period ranged from 12 weeks (n = 250) to 24 weeks (n = 41). The regimens selection was based on the American Association for the Study of Liver Disease (AASLD) guidelines [13].

ribavirin 1,000 mg/day if < 75 kg and 1,200 mg/day if ≥ 75 kg, and sofosbuvir 400 mg/day + velpatasvir (VEL) 400 mg/day. Duration of treatment period ranged from 12 weeks (n = 250) to 24 weeks (n = 41). The regimens selection was based on the American Association for the Study of Liver Disease (AASLD) guidelines [13]. Study assessments Treatment efficacy, safety, and tolerability were assessed by reviewing documented adverse events, treatment completion rates, any dosage reductions, and discontinuation of medications. Pre-treatment laboratory studies were compared with the post-treatment studies to identify any significant lab abnormalities associated with antiviral agents. The diagnosis of liver cirrhosis was based on a combination of clinical symptoms, laboratory parameters including FibroSure score ≥ 0.75, imaging modalities (USG and/or CT scan) and histopathology when indicated. We included compensated cirrhosis, defined as the presence of cirrhosis but the absence of ascites, jaundice, hepatic encephalopathy and variceal bleeding, as defined by the AASLD guidelines.

boratory parameters including FibroSure score ≥ 0.75, imaging modalities (USG and/or CT scan) and histopathology when indicated. We included compensated cirrhosis, defined as the presence of cirrhosis but the absence of ascites, jaundice, hepatic encephalopathy and variceal bleeding, as defined by the AASLD guidelines. Treatment response was assessed with HCV RNA viral load (IU/ mL) at 4 weeks after initiation of treatment, at the end of treatment, and 12 weeks after completion of therapy. The test was performed using COBAS® AmpliPrep/COBAS® TaqMan® HCV Quantitative Test, v2.0 (Roche molecular diagnostics) with the lower limit of quantification (LLOQ) of HCV RNA 15 IU/mL. HCV genotyping was assessed by polymerase chain reaction (PCR) amplification and solid-phase electrochemical detection. SVR 12 was defined as the undetectable viral load at 12 weeks after the end of treatment. Statistical analysis The SPSS® statistics software package (IBM SPSS® statistics version 21, USA) was used for statistical analysis. Values were expressed as mean ± SD and mean categorical values were analyzed using Student’s t-test. Differences in categorical values were analyzed by Chi-square test. All P-values were two-tailed and P ≤ 0.05 was considered significant. One-way analysis of variance (ANOVA) was used to determine whether there were differences among the group means. Multivariable logistic regression was performed only in variables with a P ≤ 0.05 in univariate analysis.

re analyzed by Chi-square test. All P-values were two-tailed and P ≤ 0.05 was considered significant. One-way analysis of variance (ANOVA) was used to determine whether there were differences among the group means. Multivariable logistic regression was performed only in variables with a P ≤ 0.05 in univariate analysis. Results Baseline characteristics Baseline characteristics are shown in Table 1. Mean age of the patients in the study of the cohort was 60.35 ± 10.4 years. Majority of the patients were male 179 (61.5%). Genotype 1a was the predominant HCV genotype (52.1%), followed by genotype 1b (30.1%), genotype 2 (5.5%), genotype 3 (4.1%), and genotype 4 (2%). Seventy-one patients (24.4%) had compensated cirrhosis. Two hundred and thirty-one (79.4%) were treatment-naive patients, and 60 (20.6%) were treatment-experienced with interferon-based regimens. Ninety-four patients (32.3%) had a history of diabetes, 146 had hypertension (50.2%), 26 had coronary artery disease (CAD), and 25 (8.6%) patients had chronic kidney disease (CKD). None of the patients had decompensated cirrhosis, hepatocellular carcinoma, or a previous liver transplant.

with interferon-based regimens. Ninety-four patients (32.3%) had a history of diabetes, 146 had hypertension (50.2%), 26 had coronary artery disease (CAD), and 25 (8.6%) patients had chronic kidney disease (CKD). None of the patients had decompensated cirrhosis, hepatocellular carcinoma, or a previous liver transplant. Table 1 Demographic and Clinical Characteristics of Patients at Baseline With Treatment Regimen Characteristics All patients (N = 291) Vitamin D status P-value Deficiency (< 20 ng/mL) (N = 113) Insufficiency (20 - 29.9 ng/mL) (N = 105) Normal (≥ 30 ng/mL) (N = 73) Age (years) 60.35 ± 10.407 59.52 ± 11.597 61.33 ± 8.947 60.22 ± 10.433 0.437 Gender 0.683 Male 179 (61.5%) 66 (58.4%) 67 (63.8%) 46 (63%) Female 112 (38.5%) 47 (41.6%) 38 (36.2%) 27 (37%) Race 0.051 White 43 (14.8%) 9 (8%) 24 (22.9%) 10 (13.7%) Black 200 (68.7%) 84 (74.3%) 66 (62.9%) 50 (68.5%) Asian 1 (0.3%) 1 (0.9%) 0 0 Hispanic 18 (6.2%) 5 (4.4%) 9 (8.6%) 4 (5.5%) Other 29 (10%) 14 (12.4%) 6 (5.7%) 9 (12.3%) BMI (kg/m2) 28.

(58.4%) 67 (63.8%) 46 (63%) Female 112 (38.5%) 47 (41.6%) 38 (36.2%) 27 (37%) Race 0.051 White 43 (14.8%) 9 (8%) 24 (22.9%) 10 (13.7%) Black 200 (68.7%) 84 (74.3%) 66 (62.9%) 50 (68.5%) Asian 1 (0.3%) 1 (0.9%) 0 0 Hispanic 18 (6.2%) 5 (4.4%) 9 (8.6%) 4 (5.5%) Other 29 (10%) 14 (12.4%) 6 (5.7%) 9 (12.3%) BMI (kg/m2) 28. 202 ± 5.6422 28.951 ± 5.7738 27.203 ± 5.0969 28.478 ± 6.0353 0.065 HCV genotype 0.073 1a 172 (59.1%) 67 (59.3%) 67 (63.8%) 38 (52.1%) 1b 74 (25.4%) 21 (18.6%) 31 (29.5%) 22 (30.1%) 2 13 (4.5%) 7 (6.2%) 2 (1.9%) 4 (5.5%) 3 11 (3.8%) 5 (4.4%) 3 (2.9%) 3 (4.1%) 4 21 (7.2%) 13 (11.5%) 2 (1.9%) 6 (8.2%) HCV RNA (IU/mL) 0.207 < 800,000 88 (30.2%) 30 (26.5%) 30 (28.6%) 28 (38.4%) ≥ 800,000 203 (69.8%) 83 (73.5%) 75 (71.4%) 45 (61.6%) Prior treatment 0.538 Naive 231 (79.4%) 86 (76.1%) 86 (81.9%) 59 (80.8%) Experienced 60 (20.6%) 27 (23.9%) 19 (18.1%) 14 (19.2%) Treatment regimen 0.767 LDV/SOF 184 (63.2%) 68 (60.2%) 70 (66.7%) 46 (63%) OBV/PTV/r + DSV 59 (20.3%) 25 (22.1%) 21 (20%) 13 (17.8%) SOF/VEL 48 (16.5%) 20 (17.7%) 14 (13.3%) 14 (19.2%) Comorbidities Diabetes 94 (32.3%) 38 (33.6%) 33 (31.4%) 23 (31.5%) 0.928 Hypertension 146 (50.2%) 60 (53.1%) 49 (46.7%) 37 (50.7%) 0.634 CAD 26 (8.9%) 11 (9.7%) 8 (7.6%) 7 (9.6%) 0.839 CKD 25 (8.6%) 15 (13.3%) 7 (6.7%) 3 (4.1%) 0.063 Cirrhosis < 0.001* Absent 220 (75.6%) 83 (73.5%) 68 (64.8%) 69 (94.5%) Present 71 (24.4%) 30 (26.5%) 37 (35.2%) 4 (5.5%) MELD score 0.052 < 10 207 (71.1%) 75 (66.4%) 72 (68.6%) 60 (82.2%) ≥ 10 84 (28.9%) 38 (33.6%) 33 (31.4%) 13 (17.8%) Laboratory tests Hemoglobin (g/dL) 13.236 ± 1.5712 13.165 ± 1.5414 13.470 ± 1.6247 13.011 ± 1.5151 0.131 Platelets (×103/mL) 194.19 ± 77.349 190.57 ± 73.014 191.09 ± 84.270 204.26 ± 73.552 0.439 Albumin (g/dL) 4.143 ± 5.4187 4.015 ± 3.9245 4.563 ± 8.0412 3.738 ± 0.6780 0.578 AST (IU/L) 63.02 ± 76.095 68.28 ± 91.076 67.38 ± 79.871 48.59 ± 30.368 0.173 ALT (IU/L) 65.14 ± 99.580 77.24 ± 150.455 61.74 ± 45.565 51.29 ± 35.885 0.202 Bilirubin (mg/dL) 0.903 ± 0.7806 0.905 ± 0.8913 1.047 ± 0.8281 0.693 ± 0.3913 0.012* Data presented as number/total number (percent). *Statistically significant P-values. BMI: body mass index; HCV: hepatitis C virus; RNA: ribonucleic acid; MELD: model for end-stage liver disease; ALT: alanine transaminase; AST: aspartate aminotransferase; CAD: coronary artery disease; CKD: chronic kidney disease.

.012* Data presented as number/total number (percent). *Statistically significant P-values. BMI: body mass index; HCV: hepatitis C virus; RNA: ribonucleic acid; MELD: model for end-stage liver disease; ALT: alanine transaminase; AST: aspartate aminotransferase; CAD: coronary artery disease; CKD: chronic kidney disease. Patients were divided into three groups based on pretreatment vitamin D levels. Vitamin D deficiency included 113 patients, vitamin D insufficiency included 105 patients, and normal vitamin D level included 73 patients. The three groups were similar in their baseline characteristics except for cirrhosis and bilirubin levels. The vitamin D insufficiency and vitamin D deficiency groups both had a higher incidence of cirrhotic patients (P ≤ 0.001) and elevated levels of bilirubin (P = 0.012). Treatment regimens and overall SVR 12 achievement Among the 291 patients, 184 patients (63.2%) were in the SOF/LDV group, 59 (20.3%) in the OBV/PTV/r + DSV group and 48 (16.5%) patients in the SOF/VEL group.

Patients were divided into three groups based on pretreatment vitamin D levels. Vitamin D deficiency included 113 patients, vitamin D insufficiency included 105 patients, and normal vitamin D level included 73 patients. The three groups were similar in their baseline characteristics except for cirrhosis and bilirubin levels. The vitamin D insufficiency and vitamin D deficiency groups both had a higher incidence of cirrhotic patients (P ≤ 0.001) and elevated levels of bilirubin (P = 0.012). Treatment regimens and overall SVR 12 achievement Among the 291 patients, 184 patients (63.2%) were in the SOF/LDV group, 59 (20.3%) in the OBV/PTV/r + DSV group and 48 (16.5%) patients in the SOF/VEL group. In order to identify the factors associated with the treatment failure, the univariate and multivariate analysis was performed. Patients were divided into two subgroups based on treatment response, which were the No SVR 12 group and the SVR 12 group. SVR 12 in entire cohort was 94.8%, and showed no statistically significant associations with vitamin D level, age, race, body mass index (BMI), HCV genotype, HCV viral load, HCV prior treatment status, HCV treatment regimen, model for end-stage liver disease (MELD) score, baseline aspartate aminotransferase (AST), baseline alanine aminotransferase (ALT), medical co-morbidities, baseline hemoglobin.

ations with vitamin D level, age, race, body mass index (BMI), HCV genotype, HCV viral load, HCV prior treatment status, HCV treatment regimen, model for end-stage liver disease (MELD) score, baseline aspartate aminotransferase (AST), baseline alanine aminotransferase (ALT), medical co-morbidities, baseline hemoglobin. A statistically significant difference was noted with cirrhosis status (P = 0.013) and baseline platelet counts (P = 0.018) (Table 2). After adjusting the variables and baseline characteristics in the multivariate analysis, these findings remained consistent. For cirrhosis and baseline platelet counts multivariate P-values were 0.012 and 0.017 respectively.

was noted with cirrhosis status (P = 0.013) and baseline platelet counts (P = 0.018) (Table 2). After adjusting the variables and baseline characteristics in the multivariate analysis, these findings remained consistent. For cirrhosis and baseline platelet counts multivariate P-values were 0.012 and 0.017 respectively. Table 2 Demographic and Clinical Characteristics of Patients at Baseline by Treatment Response Characteristics All patient (N = 291) Treatment response P-value No SVR 12 (N = 15) SVR 12 (N = 276) Age (years) 60.35 ± 10.407 61.47 ± 12.403 60.29 ± 10.310 0.723 Age group 0.680 < 65 189 (64.9%) 9 (60%) 180 (65.2%) ≥ 65 102 (35.1%) 6 (40%) 96 (34.8%) Sex 0.334 Male 179 (61.5%) 11 (73.3%) 168 (60.9%) Female 112 (38.5%) 4 (26.7%) 108 (39.1%) BMI (kg/m2) 28. 202 ± 5.6422 26.147 ± 4.8868 28.313 ± 5.6667 0.148 BMI (kg/m2) 0.756 < 30 183 (62.9%) 10 (66.7%) 173 (62.7%) ≥ 30 108 (37.1%) 5 (33.3%) 103 (37.3%) HCV genotype 0.285 1a 172 (59.1%) 12 (80%) 160 (58%) 1b 74 (25.4%) 1 (6.7%) 73 (26.4%) 2 13 (4.5%) 1 (6.7%) 12 (4.3%) 3 11 (3.8%) 1 (6.7%) 10 (3.6%) 4 21 (7.2%) 0 21 (7.6%) HCV RNA (IU/mL) 0.565 < 800,000 88 (30.2%) 3 (20%) 85 (30.8%) ≥ 800,000 203 (69.8%) 12 (80%) 191 (69.2%) Vitamin D status 0.214 Deficient (< 20 ng/mL) 113 (38.8%) 9 (60%) 104 (37.7%) Insufficient (20 - 29.9 ng/mL) 105 (36.1%) 4 (26.7%) 101 (36.6%) Normal (≥ 30 ng/mL) 73 (25.1%) 2 (13.3%) 71 (25.7%) Treatment Regimen 0.802 LDV/SOF 184 (63.2%) 9 (60%) 175 (63.4%) OBV/PTV/r + DSV 59 (20.3%) 4 (26.7%) 55 (19.9%) SOF/VEL 48 (16.5%) 2 (13.3%) 46 (16.7%) Prior treatment 0.521 Naive 231 (79.4%) 11 (73.3%) 220 (79.7%) Experienced 60 (20.6%) 4 (26.7%) 56 (20.3%) Comorbidities Diabetes 94 (32.3%) 5 (33.3%) 89 (32.2%) 1.000 Hypertension 146 (50.2%) 7 (46.7%) 139 (50.4%) 0.780 CAD 26 (8.9%) 0 26 (9.4%) 0.377 CKD 25 (8.6%) 2 (13.3%) 23 (8.3%) 0.376 Cirrhosis 0.013* Absent 220 (75.6%) 7 (46.7%) 213 (77.2%) Present 71 (24.4%) 8 (53.3%) 63 (22.8%) MELD score 0.381 < 10 207 (71.1%) 9 (60%) 198 (71.7%) ≥ 10 84 (28.9%) 6 (40%) 78 (28.3%) Laboratory tests Hemoglobin (g/dL) 13.236 ± 1.5712 13.627 ± 1.3828 13.215 ± 1.5803 0.324 Platelets (×1,000/mL) 194.19 ± 77.349 148.13 ± 98.694 196.69 ± 75.441 0.018* AST (IU/L) 63.02 ± 76.095 74.40 ± 50.015 339.03 ± 4639.283 0.826 ALT (IU/L) 65.14 ± 99.580 70.93 ± 62.926 64.82 ± 101.260 0.817 Bilirubin (mg/dL) 0.903 ± 0.7806 1.333 ± 1.1896 0.880 ± 0.7482 0.165 Data presented as number/total number (percent). *Statistically significant P-values.

48.13 ± 98.694 196.69 ± 75.441 0.018* AST (IU/L) 63.02 ± 76.095 74.40 ± 50.015 339.03 ± 4639.283 0.826 ALT (IU/L) 65.14 ± 99.580 70.93 ± 62.926 64.82 ± 101.260 0.817 Bilirubin (mg/dL) 0.903 ± 0.7806 1.333 ± 1.1896 0.880 ± 0.7482 0.165 Data presented as number/total number (percent). *Statistically significant P-values. BMI: body mass index; HCV: hepatitis C virus; RNA: ribonucleic acid; MELD: model for end-stage liver disease; ALT: alanine transaminase; AST: aspartate aminotransferase; CAD: coronary artery disease; CKD: chronic kidney disease. Vitamin D level and virologic response SVR 12 rates among patients with vitamin D deficiency, vitamin D insufficiency and normal vitamin D levels were 92%, 96.2%, and 97.2% respectively. SVR 12 did not show statistically significant associations with age, BMI, HCV genotype, HCV viral load, HCV prior treatment status, HCV treatment regimen, cirrhosis status, MELD score, baseline AST, ALT, baseline hemoglobin or medical co-morbidities (Table 3).

l vitamin D levels were 92%, 96.2%, and 97.2% respectively. SVR 12 did not show statistically significant associations with age, BMI, HCV genotype, HCV viral load, HCV prior treatment status, HCV treatment regimen, cirrhosis status, MELD score, baseline AST, ALT, baseline hemoglobin or medical co-morbidities (Table 3). Table 3 SVR 12 Rate in Patients Based on Vitamin D levels Characteristics Vitamin D level Deficiency Insufficiency Normal SVR 12 Univariate P-value SVR 12 Univariate P-value SVR 12 Univariate P-value Overall 104/113 (92%) N/A 101/105 (96.2%) N/A 71/73 (97.3%) N/A Age 0.455 0.643 0.535 < 65 73/78 (93.6%) 62/64 (96.9%) 45/47 (95.7%) ≥ 65 31/35 (88.6%) 39/41 (95.1%) 26/26 (100%) Sex 1.000 0.294 0.527 Male 61/66 (92.4%) 63/67 (94%) 44/46 (95.7%) Female 43/47 (91.5%) 38/38 (100%) 27/27 (100%) BMI (kg/m2) 0.301 0.580 1.000 < 30 59/66 (89.4%) 72/74 (97.3%) 42/43 (97.7%) ≥ 30 45/47 (95.7%) 29/31 (93.5%) 29/30 (96.7%) HCV genotype 0.300 0.670 0.959 1a 60/67 (89.6%) 63/67 (94%) 37/38 (97.4%) 1b 21/21 (100%) 31/31 (100%) 21/22 (95.5%) 2 6/7 (85.7%) 2/2 (100%) 4/4 (100%) 3 4/5 (80%) 3/3 (100%) 3/3 (100%) 4 13/13 (100%) 2/2 (100%) 6/6 (100%) HCV RNA (IU/mL) 0.441 1.000 1.000 < 800,000 29/30 (96.7%) 29/30 (96.7%) 27/28 (96.4%) ≥ 800,000 75/83 (90.4%) 72/75 (96%) 44/45 (97.8%) Treatment 0.699 0.019 0.547 LDV/SOF 62/68 (91.2%) 69/70 (98.6%) 44/46 (95.7%) OBV/PTV/r + DSV 24/25 (96%) 18/21 (85.7%) 13/13 (100%) SOF/VEL 18/20 (90%) 14/14 (100%) 14/14 (100%) Prior treatment 1.000 0.556 0.349 Naive 79/86 (91.9%) 83/86 (96.5%) 58/59 (98.3%) Experienced 25/27 (92.6%) 18/19 (94.7%) 13/14 (92.9%) Comorbidities Diabetes 37/38 (97.4%) 0.268 30/33 (90.9%) 0.091 22/23 (95.7%) 0.534 Hypertension 57/60 (95%) 0.301 46/49 (93.9%) 0.337 36/37 (97.3%) 1.000 CAD 11/11 (100%) 0.596 8/8 (100%) 1.000 7/7 (100%) 1.000 CKD 14/15 (93.3%) 1.000 6/7 (85.7%) 0.244 3/3 (100%) 1.000 Cirrhosis 0.243 0.124 0.107 Absent 78/83 (94%) 67/68 (98.5%) 68/69 (98.6%) Present 26/30 (86.7%) 34/37 (91.9%) 3/4 (75%) ALT (IU/L) 0.736 0.295 1.000 < 40 43/46 (93.5%) 40/40 (100.0%) 34/35 (97.1%) ≥ 40 61/67 (91%) 61/65 (93.8%) 37/38 (97.4%) Data presented as number/total number (percent). BMI: body mass index; HCV: hepatitis C virus; RNA: ribonucleic acid; MELD: model for end-stage liver disease; ALT: alanine transaminase; CAD: coronary artery disease; CKD: chronic kidney disease.

) 40/40 (100.0%) 34/35 (97.1%) ≥ 40 61/67 (91%) 61/65 (93.8%) 37/38 (97.4%) Data presented as number/total number (percent). BMI: body mass index; HCV: hepatitis C virus; RNA: ribonucleic acid; MELD: model for end-stage liver disease; ALT: alanine transaminase; CAD: coronary artery disease; CKD: chronic kidney disease. Cirrhosis and pretreatment vitamin D levels A total of 71 patients had liver cirrhosis in the study population; 30 patients were in vitamin D deficiency group, and 37 were in vitamin D insufficiency group. There was no significant difference in pretreatment mean level of vitamin D in patients with and without cirrhosis (20.90 ± 5.70 versus 23.45 ± 9.09 ng/mL). However, more cirrhotic patients had vitamin D insufficiency and deficiency compared to the non-cirrhotic patient (P ≤ 0.001) (Table 4). Table 4 Association of Vitamin D Levels With Cirrhosis Vitamin D status Cirrhosis Total (N = 291) P-value Absent (N = 220) Present (N = 71) All patients 23.452 ± 9.0978 20.901 ± 5.7075 22.830 ± 8.4601 0.006 Deficiency (< 20 ng/mL) 83 (54.6%) 30 (88.2%) 113 (60.8%) < 0.001 Insufficiency (20 - 29.9 ng/mL) 68 (49.6%) 37 (90.2%) 105 (59%) < 0.001 Data presented as number/total number (percent). Adverse effects The most common adverse effect is fatigue seen in 81(27.8%) patients across all vitamin D groups. The other adverse effects were anemia 41 (14.1%) followed by arthralgia 12(4.1%), headache 15 (5.2%). There were no severe AEs observed in the entire cohort. All patients tolerated treatment well (Table 5).

Adverse effects The most common adverse effect is fatigue seen in 81(27.8%) patients across all vitamin D groups. The other adverse effects were anemia 41 (14.1%) followed by arthralgia 12(4.1%), headache 15 (5.2%). There were no severe AEs observed in the entire cohort. All patients tolerated treatment well (Table 5). Table 5 Adverse Effects Adverse effects Vitamin D status All patients (N = 291) P-value Deficiency (N = 113) Insufficiency (N = 105) Normal (N = 73) Fatigue 32 (28.3%) 26 (24.8%) 23 (31.5%) 81 (27.8%) 0.608 Insomnia 3 (2.7%) 0 0 3 (1%) 0.092 Headache 5 (4.4%) 6 (5.7%) 4 (5.5%) 15 (5.2%) 0.902 Nausea 5 (4.4%) 5 (4.8%) 4 (5.5%) 14 (4.8%) 0.947 Diarrhea 1 (0.9%) 0 0 1 (0.3%) 0.454 Constipation 0 1 (1%) 1 (1.4%) 2 (0.7%) 0.499 Abdominal pain 3 (2.7%) 0 1 (1.4%) 4 (1.4%) 0.243 Skin rash 8 (7.1%) 4 (3.8%) 2 (2.7%) 14 (4.8%) 0.336 Arthralgia 4 (3.5%) 4 (3.8%) 4 (5.5%) 12 (4.1%) 0.793 Anemia 18 (15.9%) 11 (10.5%) 12 (16.4%) 41 (14.1%) 0.410 Data presented as number (percent). Discussion Our study gives a real-world experience of association between the vitamin D levels and the treatment response to DAAs. To our knowledge, the current study represents the largest studied cohort in published literature to date after the availability of the DAA regimens in the community care setting. Existing clinical studies have shown an excellent response to DAAs in HCV infection [14]. Our study findings are also consistent with the clinical studies with an overall SVR 12 rate of 94.8% and treatment response did not differ based on vitamin D levels.

availability of the DAA regimens in the community care setting. Existing clinical studies have shown an excellent response to DAAs in HCV infection [14]. Our study findings are also consistent with the clinical studies with an overall SVR 12 rate of 94.8% and treatment response did not differ based on vitamin D levels. Petta et al retrospectively analyzed the relationship of vitamin D levels with peg-interferon/ribavirin for hepatitis C and reported an association between lower vitamin D serum levels and failure to achieve SVR 12 [15]. However, two previous meta-analyses have evaluated associations of vitamin D and treatment outcomes in the context of interferon-based therapy with conflicting results [16, 17]. Backstedt et al evaluated the role of vitamin D levels on SVR 12 with interferon-based regimens and non-interferon based DAAs. Our study findings are consistent with their study, where pre-treatment vitamin D levels were not associated with SVR 12. A key difference in our study is the higher SVR 12 rate of 94.5 % vs. SVR 12 rate of 78 % in their study [18]. Comparing SVR 12 between cirrhotics and non-cirrhotics groups, Backstedt et al reported cirrhotic patients had SVR 12 rates of 71% versus 96% in non-cirrhotic which is again higher in our study with SVR of 86.7% in cirrhotics vs. 94 % in non-cirrhotics. The difference in the treatment response could be due to the inclusion of interferon-based regimens in that study.

hotics groups, Backstedt et al reported cirrhotic patients had SVR 12 rates of 71% versus 96% in non-cirrhotic which is again higher in our study with SVR of 86.7% in cirrhotics vs. 94 % in non-cirrhotics. The difference in the treatment response could be due to the inclusion of interferon-based regimens in that study. With the advent of newer DAAs, there are increased SVR 12 rates in clinical practice, further lessening the role of vitamin D supplementation specifically to augment the response. DAA therapy is a targeted approach where the treatment is less dependent on host immune factors, unlike peg-interferon and ribavirin [19, 20]. There is emerging data showing vitamin D deficiency being associated with advanced degrees of fibrosis in chronic HCV infection [21]. We also observed a high prevalence of vitamin D deficiency in our study population with the significantly higher number of deficiency and insufficiency of vitamin D levels in the cirrhotic subgroup, which is consistent with the published literature [18, 22]. Putz-Bankuti et al and Baur et al also observed that low levels of 25(OH)-vitamin D are associated with fibrosis and hepatic decompensation and death as well [23, 24]. DAAs included in our study were generally well tolerated, and their adverse events were consistent with other DAA based studies in the literature [14]. Common adverse effects were fatigue, headache, nausea, arthralgia, and rash. Additionally, anemia was noted in patients who were taking DAA concurrently with ribavirin. None of the patients in the study discontinued therapy due to any adverse event.

s were consistent with other DAA based studies in the literature [14]. Common adverse effects were fatigue, headache, nausea, arthralgia, and rash. Additionally, anemia was noted in patients who were taking DAA concurrently with ribavirin. None of the patients in the study discontinued therapy due to any adverse event. Our study is unique in assessing the association between the vitamin D levels and the treatment response to DAAs in CHC in a real-world community setting. This study reiterates the prevalence of vitamin D deficiency in the cirrhotic patients with HCV infection and will guide the clinicians effectively treat CHC with vitamin D insufficiency and deficiency. While our study revealed that in newer DAA therapy, vitamin D levels do not influence SVR 12, further studies are still warranted to evaluate optimal vitamin D levels in patients with cirrhosis, as vitamin D supplementation may still be of benefit due to pleiotropic effects on multiple organ systems [19, 20]. Larger randomized trials are necessary to derive more robust conclusions. Some of the limitations of the present study include a retrospective design and changes in vitamin D levels were not measured during the treatment period and after the treatment. Conclusions Based on our findings, we observed the high prevalence of vitamin D deficiency in cirrhotic populations. Despite this, pretreatment vitamin D level did not impact treatment response. DAAs are safe and effective with a high overall sustained virologic response.

Our study is unique in assessing the association between the vitamin D levels and the treatment response to DAAs in CHC in a real-world community setting. This study reiterates the prevalence of vitamin D deficiency in the cirrhotic patients with HCV infection and will guide the clinicians effectively treat CHC with vitamin D insufficiency and deficiency. While our study revealed that in newer DAA therapy, vitamin D levels do not influence SVR 12, further studies are still warranted to evaluate optimal vitamin D levels in patients with cirrhosis, as vitamin D supplementation may still be of benefit due to pleiotropic effects on multiple organ systems [19, 20]. Larger randomized trials are necessary to derive more robust conclusions. Some of the limitations of the present study include a retrospective design and changes in vitamin D levels were not measured during the treatment period and after the treatment. Conclusions Based on our findings, we observed the high prevalence of vitamin D deficiency in cirrhotic populations. Despite this, pretreatment vitamin D level did not impact treatment response. DAAs are safe and effective with a high overall sustained virologic response. Conflict of Interest Dr. Mohanty is on the Speakers Bureau for Gilead Science, BMS, and Abbvie Pharmaceuticals. For the remaining authors, there is no conflict of interest. Funding None.

Conclusions Based on our findings, we observed the high prevalence of vitamin D deficiency in cirrhotic populations. Despite this, pretreatment vitamin D level did not impact treatment response. DAAs are safe and effective with a high overall sustained virologic response. Conflict of Interest Dr. Mohanty is on the Speakers Bureau for Gilead Science, BMS, and Abbvie Pharmaceuticals. For the remaining authors, there is no conflict of interest. Funding None. Author Contributions Vijay Gayam: substantial contribution to conception and design of the study, data acquisition, analysis, interpretation of the data and drafting of the manuscript; and performed critical reviews, communicated with the journal, and addressed comments from the reviewers. Amrendra Kumar Mandal and Mazin Khalid: data acquisition and provided assistance with interpretation of data and drafting of the manuscript. Osama Mukhtar: substantial contribution to statistical data analysis and interpretation of the data. Pavani Garlapati, Tiongson Benjamin, and Arshpal Gill have contributed in the acquisition of the patient data. Sherigar Jagannath, Mohammad Mansour, and Smruti Mohanty did critical review of the manuscript. All the authors vouch for the veracity and completeness of the data presented and agreed to submit the manuscript for publication. Abbreviations DAAsdirect-acting antivirals AEadverse event HCVhepatitis C virus HCChepatocellular cancer GTgenotype SVR12sustained virologic response at 12 weeks post-treatment LDVledipasvir SOFsofosbuvir VELvelpatasvir RBVribavirin OBVombitasvir PTV/rparitaprevir/ritonavir DSVdasabuvir